NAFDAC Registration & Regulatory Affairs (R & R) Director Guidelines for Registration of Imported Drugs, Vaccines and In-Vitro Diagnostics Under WHO collaborative Registration Procedure (CRP)
Ministry of Health, National Agency for Food and Drug Administration and Control, Nigeria
These guidelines are for the interest of the general public and in particular manufacturers/importers of drugs, vaccines and in-vitro diagnostics into the county which has been prequalified by the World Health Organization. This guideline is based on NAFDAC’s regulatory reliance policy on the adoption of a regulatory reliance mechanism to make regulatory decisions as it relates to the granting of marketing authorization. Clinical trial approval and conduct of Good Manufacturing Practice (GMP) Inspections.
You are viewing a previous version. Click here to view the current version.
Read in full screenProcess Flow
Department of Registration and Regulatory Affairs ⬤
Office of the Director General NAFDAC ⬤
Office of the Permanent Secretary, Ministry of Health ⬤
Office of the Minister of State for Health ⬤
Office of the minister for health ⬤
Federal Executive Council ⬤
NAFDAC Registration & Regulatory Affairs (R & R) Director Guidelines for Registration of Imported Drugs, Vaccines and In-Vitro Diagnostics Under WHO collaborative Registration Procedure (CRP) Current Version
January 2022
These guidelines are for the interest of the general public and in particular manufacturers/importers of drugs, vaccines and in-vitro diagnostics into the county which has been prequalified by the World Health Organization. This guideline is based on NAFDAC’s regulatory reliance policy on the adoption of a regulatory reliance mechanism to make regulatory decisions as it relates to the granting of marketing authorization. Clinical trial approval and conduct of Good Manufacturing Practice (GMP) Inspections.
Thank you for requesting an expert analysis
A member of our team will review your request and reply back to the email address on file.